Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study

Agréus L, Svärdsudd K, Nyrén O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3):671–680

Husain N, Chaudhry IB, Jafri F, Niaz SK, Tomenson B, Creed F (2008) A population-based study of irritable bowel syndrome in a non-Western population. Neurogastroenterol Motil 20(9):1022–1029

Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47(1):225–235

Wilson S, Roberts L, Roalfe A, Bridge P, Singh S (2004) Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54(504):495–502

Markowitz MA, Jhingran P, Asgharian A, Harris WA, Brod M, Wentz AL, Gordon SH, Carter E (2000) IBS prevalence: results from a community based patient registry based on the Rome II criteria. Am J Gastroenterol 95:2634

Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10(7):712–721

Schmulson MJ, Drossman DA (2017) What is new in Rome IV. J Neurogastroenterol Motil 23(2):151–163

Ford AC, Tally NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P (2008) Effect of fibre, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313

Gibson PR (2017) History of the low FODMAP diet. J Gastroenterol Hepatol 32:5–7

Eswaran S (2017) Low FODMAP in 2017: lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil 29:e13055

Nanayakkara WS, Skidmore PM, O’Brien L, Wilkinson TJ, Gearry RB (2016) Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol 9:131–142. https://doi.org/10.2147/CEG.S86798

Barrett JS (2017) How to institute the low-FODMAP diet. J Gastroenterol Hepatol 32(Suppl 1):8–10

Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142(8):1510–1518

Canavan C, West J, Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6:71–80. https://doi.org/10.2147/CLEP.S40245

Marsh A, Eslick EM, Eslick GD (2015) Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 55(3):897–906

Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64:93–100

O’Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Whelan K, Lomer MC (2018) Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 30(1):712–721

Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR (2016) Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 44:447–459